Flagship explainer
What drives HALOZYME THERAPEUTICS, INC.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| $317M | FY2025 |
| |
| Income before tax | $467M | FY2025 |
|
| Operating income | $469M | FY2025 |
|
| $1.4B | FY2025 |
| |
| Ending assets | $2.5B | FY2025 |
|
| Beginning assets | $2.1B | FY2024 |
|
| $48.8M | FY2025 |
| |
| $364M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001159036-26-000024